Alkermes (ALKS) Q3 2026 Earnings Call Transcript

Alkermes (ALKS) reported Q3 2026 net sales of $417.3M, up 31% YoY. Key products include VIVITROL ($127.6M), ARISTADA ($103.9M), LYBALVI ($95.9M), and LUMRYZ ($89.9M). Full-year guidance remains unchanged. The company expects continued growth in 2027 and beyond, driven by expanded payer access and new product launches.

Original reporting
Published Nov 3, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alkermes (ALKS) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ALKSBullishHigh
01

Why it matters

The earnings beat and raised guidance suggest continued revenue momentum, supporting a bullish stance.

02

Market read

Earnings release provides fresh material for traders; strong sales may drive short-term upside.

03

What to watch

Potential headwinds from regulatory reviews of new products and competition in addiction treatments.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

Alkermes reported Q3 2026 financial results, highlighting growth in its proprietary portfolio and upcoming product launches.

Company-level read

Ticker impact

$ALKSBullishHigh confidence
Context

Q3 2026 earnings call disclosed net sales of $417.3M, 31% YoY growth and strong product performance.

Expected impact

likely upward pressure as investors price in higher revenue and guidance.

Evidence & confidence

The disclosed sales figures and guidance ranges exceed prior expectations, supporting a bullish outlook.

Market effects

Strong results may lift the broader neuropsychiatric biotech sector.

Positive impact on US biotech indices.

Limited to US-listed biotech investors.

Counterpoint

If guidance falls short of market expectations, the stock could face a pullback.

Key entities

  • Alkermes

    US-listed biopharma focused on neuropsychiatric treatments.

Related articles

$TAKHighAI 8/10

Awake to the possibilities: a ‘first in class’ narcolepsy drug could be transformational

Takeda's narcolepsy drug Orzeyful (oveporexton), approved by the FDA in 2026, targets the underlying cause of type 1 narcolepsy by activating orexin receptors. The drug, taken twice daily, shows immediate effects but has some side effects. Takeda seeks UK approval. Other companies like Eli Lilly, Alkermes, and Lundbeck are also developing orexin agonists for sleep disorders. (350 characters)

$ALKSMed

H.C. Wainwright raises Alkermes stock price target to $50 on pipeline progress

H.C. Wainwright raised its price target for Alkermes (ALKS) to $50 from $43, citing progress in its clinical pipeline and commercial revenue. The stock is up 63% year-to-date. The firm maintained a Neutral rating. Alkermes recently reported stronger-than-expected Q3 2026 results, with adjusted earnings of $0.09 per share and revenue of $480.1 million. Baird and Wells Fargo also raised their price targets.

$ALKSMed

Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31%

Alkermes PLC (ALKS) reported a 31% surge in proprietary sales for Q3 2026, but R&D and SG&A expenses rose due to the Avadel acquisition and expanded orexin development. LYBALVI's gross-to-net adjustments are expected to reach 45% in 2027, potentially pressuring net sales growth. The company faces competition from Takeda's oveporexton in the narcolepsy market. Alkermes expects to provide full 2027 financial guidance in February, leaving investors with uncertainty.

$ALKSMed

What Alkermes (ALKS) Said on Its Q3 Earnings Call

Alkermes (ALKS) expects Q4 proprietary product net sales of $400M-$420M and $1.6B for full-year 2026. Q3 GAAP net income was $16.3M, EBITDA $63M, and cash $787.6M. The company is advancing its orexin pipeline, with Phase III trials for alixorexton in narcolepsy and IH, and Phase II trials for ALKS 7290 in ADHD and depression.